Stengone Carmine N.
- SEC CIK
- 0001861519
In the past year, 6 open-market sale filings worth $401.4K and no purchases.
Current role at each company
- CTNM Contineum Therapeutics, Inc.CEO and Presidentas of Sep 8, 2026
- KPRX Kiora Pharmaceuticals IncDirectoras of Jun 12, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $401.4K
- 6 filings
- Net
- −$401.4K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Stengone Carmine N. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
CTNM Contineum Therapeutics, Inc.
CEO and President6 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 (view filing)6:08 PM ET | Sep 8 | Same day | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −2.50K | $16.46 | −$41.1K | −12.7%17.2K after | 10b5-1 |
| Aug 3, 2026 (view filing)6:14 PM ET | Aug 3 | Same day | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −2.50K | $16.01 | −$40.0K | −12.7%17.2K after | 10b5-1 |
| Jul 8, 2026 (view filing)6:49 PM ET | Jul 8 | Same day | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −2.50K | $16.00 | −$40.0K | −12.7%17.2K after | 10b5-1 |
| Jul 1, 2026 (view filing)7:04 PM ET | Jun 30 | 1 day | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −10.0K | $16.01 | −$160.1K | −36.7%17.2K after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 24-25 | 2 days | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −7.10K | $16.02 | −$113.7K | −32.2%15.0K after | 2 lots10b5-1 |
| Feb 13, 2026 (view filing) | Feb 11 | 2 days | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −400 | $16.00 | −$6.40K | −2.6%15.0K after | 10b5-1 |
KPRX Kiora Pharmaceuticals Inc
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 12, 2024 (view filing) | Sep 11 | 1 day | Stengone Carmine N.Director | PPurchase | +1.25K | $3.68 | +$4.60K | New position1.25K after |